Search details
1.
Non-viral precision T cell receptor replacement for personalized cell therapy.
Nature
; 615(7953): 687-696, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36356599
2.
Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects.
Blood
; 138(24): 2583-2588, 2021 12 16.
Article
in English
| MEDLINE | ID: mdl-34424962
3.
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Blood
; 138(1): 11-22, 2021 07 08.
Article
in English
| MEDLINE | ID: mdl-33827116
4.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Lancet
; 398(10299): 491-502, 2021 08 07.
Article
in English
| MEDLINE | ID: mdl-34097852
5.
Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
Biol Blood Marrow Transplant
; 23(1): 30-37, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27815049
6.
Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response.
Prostate
; 76(14): 1257-70, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27324746
7.
Treatment of chronic graft-versus-host disease with bortezomib.
Blood
; 124(10): 1677-88, 2014 Sep 04.
Article
in English
| MEDLINE | ID: mdl-25009225
8.
Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells.
Stem Cells
; 33(3): 870-9, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25524029
9.
Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia.
Am J Hematol
; 96(4): E114-E117, 2021 04 01.
Article
in English
| MEDLINE | ID: mdl-33476436
10.
The path(way) less traveled.
Blood
; 122(12): 1996-7, 2013 Sep 19.
Article
in English
| MEDLINE | ID: mdl-24052539
11.
Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.
Biol Blood Marrow Transplant
; 20(12): 1899-904, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25064746
12.
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Br J Haematol
; 165(3): 375-81, 2014 May.
Article
in English
| MEDLINE | ID: mdl-24606326
13.
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.
Am J Hematol
; 94(11): E291-E294, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31379016
14.
IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
J Immunol
; 189(4): 2033-42, 2012 Aug 15.
Article
in English
| MEDLINE | ID: mdl-22778394
15.
Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice.
Proc Natl Acad Sci U S A
; 108(2): 762-7, 2011 Jan 11.
Article
in English
| MEDLINE | ID: mdl-21187385
16.
Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.
J Virol
; 86(10): 5719-29, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22398281
17.
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.
Transplant Cell Ther
; 29(7): 460.e1-460.e9, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37086851
18.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
J Immunother Cancer
; 11(8)2023 08.
Article
in English
| MEDLINE | ID: mdl-37648261
19.
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
J Exp Clin Cancer Res
; 41(1): 344, 2022 Dec 14.
Article
in English
| MEDLINE | ID: mdl-36517865
20.
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Leuk Res
; 119: 106885, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35738024